Pharma major Lupin Ltd announced on Monday (May 18) that it has received tentative approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Revefenacin Inhalation Solution, 175 mcg/3 mL unit-dose vials. According to reports from CNBC TV18, the product is bioequivalent to Mylan's Yupelri inhalation solution and is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). The referenced product had estimated annual sales of $260.7 million in the US, based on IQVIA MAT March 2026 data. However, as reported by The Economic Times, the approval comes with a 'tentative' status, meaning the FDA has completed its review and found the drug approvable, but it cannot be marketed until existing patents or exclusivities on the reference drug expire, potentially delaying market entry. This regulatory step is significant for Lupin, potentially bolstering its respiratory drug portfolio in the U.S. market.
Last week, Lupin received approval from the US FDA for its abbreviated new drug application (ANDA) for famotidine injection USP, 20 mg/2 mL (10 mg/mL), single-dose vials. As reported by CNBC TV18, the product is bioequivalent to the reference listed drug (RLD), Pepcid injection, 10 mg/mL, manufactured by Merck Sharp & Dohme Corp. The drug is indicated for intravenous use in certain hospitalised patients with pathological hypersecretory conditions or intractable ulcers, and is also used as an alternative to oral dosage forms for short-term use in patients who are unable to take oral medication. According to The Economic Times, this injectable, manufactured at Lupin's Nagpur facility in India, addresses a U.S. market estimated at $8.7 million annually, though the overall Famotidine market exceeds $3 billion.
According to The Economic Times, Lupin is strategically expanding into complex generics and injectables to diversify revenue and achieve higher margins, shifting away from the crowded oral generics market. The COPD market, though large, is highly competitive with major players like Boehringer Ingelheim, GSK, Pfizer, and Teva, where Yupelri holds a small 2-3% market share. The $8.7 million annual market for Famotidine Injection is a small contribution, though the broader COPD drug market is substantial, valued at approximately $24.67 billion in 2024 and projected to reach $35.15 billion by 2032, growing at a 4.9% CAGR. The company also markets COPD products like Vilfuro-G in India. The primary risk for Lupin is the tentative nature of the Revefenacin approval, requiring the company to fulfill outstanding FDA conditions for final clearance and commercial launch. Major Indian pharmaceutical players such as Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., and Cipla Ltd. also maintain strong U.S. presences and compete in similar therapeutic areas.
As reported by The Economic Times, the U.S. pharmaceutical sector is currently experiencing slower growth with net price increases forecast between 4.5-7.5% through 2030, down from prior periods, due to pricing pressures and patent expiries. The Inflation Reduction Act (IRA), which began affecting Medicare Part D drug prices in January 2026, adds to these pricing challenges. Investors are showing caution for several reasons, including the 'tentative' status of the Revefenacin approval and the small market size for Famotidine Injection. Additionally, Lupin has faced prior regulatory scrutiny, including FDA observations at its Nagpur manufacturing unit in September 2025, raising questions about compliance and production reliability. High competition from players like Mylan (Viatris) in COPD and Merck in GI also limits immediate upside. Future monitoring will focus on confirmation of final FDA approval, Lupin's launch strategy and timeline, market reception, and the performance of Lupin's broader respiratory segment.
Despite the current stock underperformance and investor concerns, analysts generally maintain a positive outlook with a consensus rating of 'Moderate Buy', as reported by The Economic Times. The average 12-month price targets around ₹2,460 suggest an expected upside of approximately 9-11% from current levels. This optimism is likely based on Lupin's strategic shift toward complex generics, biosimilars, and injectables, alongside its expanding global reach. The company's ability to navigate U.S. pricing dynamics and successfully commercialize its product pipeline will be key to its stock performance in the coming quarters. A successful launch of Revefenacin could contribute positively to revenue by tapping into a substantial market for COPD treatments, underscoring Lupin's capabilities in developing complex generic medications for key international markets.
